•
Jun 30, 2022
Mink Therapeutics Q2 2022 Earnings Report
Mink Therapeutics reported financial results for the second quarter of 2022 and provided a corporate update.
Key Takeaways
MiNK Therapeutics reported a net loss of $6.1 million for the second quarter of 2022, with a cash balance of $29.8 million at the end of the quarter.
Ended the second quarter 2022 with a cash balance of $29.8 million.
Cash used in operations for the second quarter ended June 30, 2022, was $4.6 million.
Net loss for the quarter ended June 30, 2022, was $6.1 million or $0.18 per share.
Company is on track to present clinical data updates from lead program, AgenT-797.